Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;34(6):752-6.
doi: 10.1016/j.leukres.2009.10.001. Epub 2009 Oct 29.

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Farhad Ravandi  1 , Hagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, Susan O'Brien, Charles Koller, Sherry Pierce, Mark Brandt, Deborah Kennedy, Jorge Cortes, Miloslav Beran
Affiliations

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Farhad Ravandi et al. Leuk Res. 2010 Jun.

Abstract

Mutations of Fms-like tyrosine kinase-3 (FLT3) have been described in about 30% of patients with acute myeloid leukemia (AML) and are associated with a shorter disease-free and overall survival after initial therapy. We sought to examine whether the presence of these mutations in relapsed disease was also associated with a poor response to salvage chemotherapy by comparing the outcome of 34 patients with diploid cytogenetics and mutated FLT3 (internal tandem duplication mutation, ITD) to 69 patients with normal karyotype and wild-type FLT3 (FLT3-WT) in first relapse. On univariate analysis, patients with mutated FLT3 were less likely to achieve a CR to first salvage compared to FLT3-WT patients (24% vs. 41%; P=0.09). Furthermore, survival was longer for the FLT3-WT patients achieving a second CR after salvage compared to FLT3-mutated patients (P=0.017). Overall, patients with mutated FLT3 had a shorter survival from the time of relapse compared to those with FLT3-WT (P<0.001). The adverse prognostic impact of FLT3 mutations appears to persist beyond the initial treatment.

PubMed Disclaimer

Figures

Fig 1
Fig 1
a – Overall survival from the time of relapse for all patients in first relapse by FLT3 status. b - Survival for patients who achieved CR to first salvage. Time is in Weeks from relapse date to last follow-up. c - Survival for patients who were resistant to first salvage. Time is in Weeks from relapse date to last follow-up. d - CR Duration after first Salvage therapy –Time is indicated in Months from date of second CR to either relapse or last follow-up.
Fig 1
Fig 1
a – Overall survival from the time of relapse for all patients in first relapse by FLT3 status. b - Survival for patients who achieved CR to first salvage. Time is in Weeks from relapse date to last follow-up. c - Survival for patients who were resistant to first salvage. Time is in Weeks from relapse date to last follow-up. d - CR Duration after first Salvage therapy –Time is indicated in Months from date of second CR to either relapse or last follow-up.
Fig 1
Fig 1
a – Overall survival from the time of relapse for all patients in first relapse by FLT3 status. b - Survival for patients who achieved CR to first salvage. Time is in Weeks from relapse date to last follow-up. c - Survival for patients who were resistant to first salvage. Time is in Weeks from relapse date to last follow-up. d - CR Duration after first Salvage therapy –Time is indicated in Months from date of second CR to either relapse or last follow-up.
Fig 1
Fig 1
a – Overall survival from the time of relapse for all patients in first relapse by FLT3 status. b - Survival for patients who achieved CR to first salvage. Time is in Weeks from relapse date to last follow-up. c - Survival for patients who were resistant to first salvage. Time is in Weeks from relapse date to last follow-up. d - CR Duration after first Salvage therapy –Time is indicated in Months from date of second CR to either relapse or last follow-up.
See this image and copyright information in PMC

References

    1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 1;100(5):1532–1542. - PubMed
    1. Brasel K, Escobar S, Anderberg R, et al. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia. 1995 Jul;9(7):1212–1218. - PubMed
    1. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996 Apr;10(4):588–599. - PubMed
    1. Turner AM, Lin NL, Issarachai S, et al. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 1996 Nov 1;88(9):3383–3390. - PubMed
    1. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 1992 Nov 15;80(10):2584–2593. - PubMed

Publication types

MeSH terms

Substances